BIO Double Helix Sponsor
Sponsors

Company Profile

NanoMed Pharmaceuticals

Cancer
Infectious Diseases
CNS

7107 Elm Valley Drive
Room B1210
Kalamazoo, MI 49009
USA
www.nanomedpharm.com 		Incorporated in 2000
2 Employees 		Privately Held

This Year's Highlights

  • US patent 7,153,525 issued covering Nanotemplate Engineering.
  • Lead oncology product overcame pgp resistance in human HL-60/VCR cells in vitro, and significantly reduced IC50 in MRP-1 resistant HL-60/ADR cells in vitro.
  • Pre-IND meeting with FDA successful; clear path to filing IND in Q2 2008.

Anticipated Highlights

  • Close $1.5 million Series A-2 financing (Q3 2007).
  • Lead oncology product overcame pgp resistance in vivo (Q3 2007); GLP safety/tox studies completed (Q1 2008); GMP manufacture of clinical materials completed (Q2 2008).
  • IND filed (Q2 2008); Phase I/II clinical trial begun (Q3 2008).

Corporate Mission

NanoMed PharmaceuticalsŪ is an early-stage specialty pharmaceutical company dedicated to developing improved therapeutic and diagnostic products to treat or detect cancer and other serious diseases.